Last updated 16 days ago
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
4500 patients around the world
Available in Brazil, Argentina, United States, Mexico
Eli Lilly and Company
21Research sites
4500Patients around the world
This study is for people with
Fatty Liver
Hepatic Steatosis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have liver fat content ≥8%.Have ELF score of ≥9 and ≤10.8 at screening.Have VCTE LSM ≥10 kilopascal (kPa) and <20 kPa at screening.
- Have any other type of liver disease other than MASLD.Have a body mass index (BMI) <25 kilogram per square meter (kg/m2).Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy).Have lost more than 11 pounds within the 3 months prior to screening.Have a hemoglobin A1c (HbA1c) greater than 10%.Have type 1 diabetes.
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro Médico Viamonte SRL - CABA, Buenos Aires
Instituto de Investigaciones Clínicas Mar del Plata
CEDIMBA - DIM Clínica Privada - Buenos Aires
Centro de Investigaciones Clínicas - IESR - Rosario, Santa Fe
Centro Médico Maffei - CABA, Buenos Aires
Instituto de Investigaciones Clínicas Córdoba
Consultorio de Investigación Clínica EMO SRL
INECO Neurociencias Oroño - Rosario
Centro de Diagnóstico y Rehabilitación - CEDIR
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Hepatic Steatosis
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07165028
